Furthermore, we tested whether this combination affected the CCL19-mediated migration by chemotaxis assays, revealing that the drug combination at non-cytotoxic doses significantly reduced migration of CLL cell lines towards CCL19 (Supplementary Fig. S5f). Here, CCL19 is linked to B-cell chronic lymphocytic leukemia.